A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

Mark A. Chambers; D. Craig Wright; Joan Brisker; Ann Williams; Graham Hatch; Dolores Gavier-Widén; Graham Hall; Philip D. Marsh; R. Glyn Hewinson

doi:10.1016/j.vaccine.2003.05.002

A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

Mark A. Chambers^*, D. Craig Wright, Joan Brisker, Ann Williams, Graham Hatch, Dolores Gavier-Widén, Graham Hall, Philip D. Marsh, R. Glyn Hewinson

^*Corresponding author for this work

Biological Investigations Group

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes™) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown

Original language	English
Pages (from-to)	1063-1071
Number of pages	9
Journal	Vaccine
Volume	22
Issue number	8
DOIs	https://doi.org/10.1016/j.vaccine.2003.05.002
Publication status	Published - 25 Feb 2004

Bibliographical note

Funding Information:
We thank the Animal Services Units at VLA Weybridge and CAMR. This work was supported by the Ministry of Agriculture, Fisheries, and Food, GB, now the Department of Environment, Food and Rural Affairs (DEFRA).

Keywords

Liposome
M. bovis
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2003.05.002

Cite this

@article{77b897dc1d594e9181ff0de3224cddf0,

title = "A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome{\texttrademark}) protects guinea pigs from lethal tuberculosis",

abstract = "The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes{\texttrademark}) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown",

keywords = "Liposome, M. bovis, Vaccine",

author = "Chambers, {Mark A.} and Wright, {D. Craig} and Joan Brisker and Ann Williams and Graham Hatch and Dolores Gavier-Wid{\'e}n and Graham Hall and Marsh, {Philip D.} and Hewinson, {R. Glyn}",

note = "Funding Information: We thank the Animal Services Units at VLA Weybridge and CAMR. This work was supported by the Ministry of Agriculture, Fisheries, and Food, GB, now the Department of Environment, Food and Rural Affairs (DEFRA). ",

year = "2004",

month = feb,

day = "25",

doi = "10.1016/j.vaccine.2003.05.002",

language = "English",

volume = "22",

pages = "1063--1071",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

AU - Chambers, Mark A.

AU - Wright, D. Craig

AU - Brisker, Joan

AU - Williams, Ann

AU - Hatch, Graham

AU - Gavier-Widén, Dolores

AU - Hall, Graham

AU - Marsh, Philip D.

AU - Hewinson, R. Glyn

N1 - Funding Information: We thank the Animal Services Units at VLA Weybridge and CAMR. This work was supported by the Ministry of Agriculture, Fisheries, and Food, GB, now the Department of Environment, Food and Rural Affairs (DEFRA).

PY - 2004/2/25

Y1 - 2004/2/25

N2 - The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes™) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown

AB - The only vaccine currently available for the prevention of tuberculosis in man is a live attenuated vaccine, bacille Calmette-Guerin (BCG), derived from Mycobacterium bovis. Concerns over the lack of the universal efficacy and safety of BCG have resulted in efforts to develop a new generation of TB vaccines. Historically, killed whole-cell preparations of mycobacteria have been ineffective vaccines. We revisited the potential of killed whole-cell vaccines by comparing their efficacy with live BCG Pasteur in a guinea pig challenge model. BCG Pasteur was inactivated with a low concentration of formalin and showed to be non-viable in culture or severe combined immunodeficient mice. Formalin-inactivated BCG was mixed with non-phospholipid liposome adjuvants (Novasomes™) and administered to guinea pigs as a single subcutaneous inoculation. All formulations were well tolerated and one conferred a significant survival advantage against lethal aerogenic challenge with M. bovis. Crown

KW - Liposome

KW - M. bovis

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=1242270634&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2003.05.002

DO - 10.1016/j.vaccine.2003.05.002

M3 - Article

C2 - 15161084

AN - SCOPUS:1242270634

SN - 0264-410X

VL - 22

SP - 1063

EP - 1071

JO - Vaccine

JF - Vaccine

IS - 8

ER -

A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this